New York || 10:39 AM ET – plunging 30.7% to $43.00, down from Friday’s close, after Novo Nordisk abruptly terminated a critical partnership.
Trading volume surged to 39.90 million shares, nearly matching the three-month average, reflecting investor alarm. Despite the plunge, HIMS remains up 83.30% year-to-date (YTD), highlighting its volatile rally.
Why is Hims & Hers Falling Today?
The sell-off is driven by fundamental blows to Hims & Hers’ weight-loss business.
Novo Nordisk (NYSE: NVO) ended a monthlong partnership formed in April 2025 to transition patients from compounded versions of its blockbuster GLP-1 drug Wegovy to branded prescriptions.
Novo Nordisk alleged Hims engaged in “illegal mass compounding” and “deceptive promotion” of unapproved Wegovy knockoffs, which violated laws prohibiting mass sales of compounded drugs under the guise of personalization. The Danish drugmaker, whose own stock dipped 5.15%, stated it would no longer allow Wegovy to be bundled with Hims’ $599/month membership, a key growth driver.
The partnership’s collapse threatens Hims’ $725 million 2025 weight-loss revenue target, with compounded semaglutide accounting for ~25% of 2024 sales ($225 million).
Regulatory risks compound the issue: the FDA’s February 2025 removal of semaglutide from its shortage list, followed by a crackdown on compounders, already disrupted Hims’ GLP-1 supply. Hims’ pivot to oral medications and generic liraglutide has underperformed, per Leerink analyst Michael Cherny.
Additionally, Hims issued a surprise guidance cut on June 23, lowering its 2025 EBITDA forecast by 18% due to a 15% year-over-year rise in customer acquisition costs (CAC) and a 200-basis-point margin decline. Competition from Teladoc and GoodRx has squeezed Hims’ 2.4 million subscriber base (up 38% YoY), slowing core revenue growth from 45% in Q3 2024 to 29% in Q1 2025.
Also Read – Top 7 Stocks That May Benefit from a Strait of Hormuz Closure
Hims & Hers Stock Price June 23, 2025 – Key Metrics
Hims & Hers’ financials reflect its high-risk profile:
| Metric | Value |
|---|---|
| Market Cap | $9.98 Billion |
| EPS (TTM) | $0.68 |
| Forward EPS (2025E) | $0.65(Est) |
| YTD Performance | 83.30% |
| Shares Outstanding | 213.73M* |
| Beta | 3.22 |
The P/E ratio stands at 65.78, meaning investors are willing to pay $65.78 for every $1 of earnings.
Hims and Hers Health Stock Outlook June 2025
As of 10:39 AM, bearish sentiment prevails.
The stock’s RSI of 39 indicates oversold conditions, but the compounding scandal and guidance cut deter buyers.
HIMS is trading at its $45 support level; a breach could drive it to the next crucial support zone at $39–$36. If it recovers, $52–$54 may act as resistance, potentially leading to rangebound trading between $36 and $52 for several days. These technical levels are speculative and not investment advice.
A shift to oral medications or European growth via ZAVA could spur recovery, but for now, the compounding scandal keeps HIMS a high-risk play.
This article is for informational purposes only and not financial advice. Investing in stocks involves risks, including potential loss of principal. Conduct your own research or consult a qualified financial advisor before investing. The author and publisher are not liable for losses from actions based on this article. Data accuracy is not guaranteed due to changing market conditions.
Dawson Blake is a financial markets expert with over 10 years of experience, focusing mainly on stock market news and price movements. He aims to become a top-tier authority in curating stock news content that readers can trust as their go-to source for market information. Dawson enjoys breaking down market activity, company updates, and daily trends to help investors stay informed and make smarter financial decisions. His writing is simple, clear, and designed to make the stock market easy to follow for everyone.